Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047616 · ClinicalTrials.gov registry record
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 88
- Enrollment target
NCT03047616 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 88 participants.
The verdict
NCT03047616 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
Interventions
- OTHER Blood and Urine Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2016-11-22 |
| Est. Completion | 2019-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03047616
The ClinicalTrials.gov registry entry for NCT03047616 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood and Urine Collection is the first listed.
NCT03047616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03047616 about?
NCT03047616 is a clinical study titled "A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer". Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1...
What is the current status of trial NCT03047616?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2016-11-22. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT03047616?
The interventions under investigation include: Blood and Urine Collection (OTHER).
Who is sponsoring clinical trial NCT03047616?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.